The PATH Malaria Vaccine Initiative's (MVI) mission is to accelerate the development of malaria vaccines and ensure their availability and accessibility in the developing world. The website contains information on malaria and potential …

This report provides an overview of a 2001 meeting of experts that reviewed the malaria vaccine market and identified gaps in essential economic and market information needed to inform decision-makers and ultimately drive the funding/investment …

While progress has been made in reducing malaria mortality with other interventions, vaccines are still urgently needed to further reduce the incidence of clinical disease. The most clinically advanced candidate, RTS,S, is presently undergoing Phase …

This report on the Malaria Vaccine Technology Roadmap establishes a strategic plan for developing and distributing a safe, effective, and affordable vaccine to prevent malaria in children under five years of age in sub-Saharan Africa and other …

This review, published in Frontiers in Bioscience, discusses the life cycle of malaria parasites and the different vaccine candidates aimed at preventing malaria at various stages of the parasites' life cycle. ABSTRACT ONLY. (Learn …

This document provides an overview of Medicines for Malaria Venture's activities and achievements.

This web page on the Vaccine Resource Library provides links to PATH's work on malaria, as well as general information about the disease and the current vaccine landscape.

This article, which appeared in the American Journal of Tropical Medicine and Hygiene, describes a cross-sectional study conducted in Kenya’s Nyanza Province to investigate the burden of viral respiratory disease, including influenza, in …

This fact sheet gives an overview of the PATH Malaria Vaccine Initiative (MVI), a vaccine development program of PATH. Established in 1999, MVI works to accelerate the development of malaria vaccines and to ensure their availability and …

This article, published in the New England Journal of Medicine (NEJM), reports results from a pivotal, large-scale Phase 3 trial of RTS,S/AS01 malaria vaccine. When compared to immunization with a control vaccine, infants (aged 6 to 12 weeks at …

This review, published in Expert Review of Vaccines, outlines the developmental status of all malaria vaccine candidates that are currently in human clinical testing against Plasmodium falciparum, as well as selected malaria vaccine candidates at …

In this five-minute video, scientist-advocates describe their critical role in closing the gap between the availability of lifesaving interventions and developing countries' access to them. A malaria vaccine could be available in just a few short …

This fact sheet describes how PATH developed a low-cost and straightforward technology for protecting aluminum-adjuvanted liquid vaccines from the irreversible damage that results from freezing. Many current vaccines of importance to global …

This fact sheet provides a snapshot of PATH's programs that tackle the leading causes of childhood illness and death: pneumonia, diarrheal disease, and malaria. It profiles PATH's work on new and innovative vaccines, medicines, diagnostics, and …

Vaccines that interrupt malaria transmission are of increasing interest. A robust functional assay to measure this activity would provide a biologically relevant means of evaluating potential vaccine candidates. This article, published in PLOS ONE, …

This study, published in the New England Journal of Medicine, assessed the feasibility of integrating the RTS,S/AS02D malaria vaccine into a standard expanded program on immunization (EPI) schedule for infants. The study, conducted in …

This study, published in the journal Vaccine, evaluated the safety of the RTS,S/AS02A malaria vaccine in a proof of concept Phase IIb trial in Mozambican children aged one to four years. Overall, the study results indicate that the …

This document analyzes research and development activities for vaccines against infectious diseases of public health importance. Disease groups covered include diarrheal disease, sexually transmitted diseases, respiratory infections, bacterial …

This technical report from the Roll Back Malaria Partnership shines a spotlight on recent trends in investments in malaria research and development (R&D). The report follows up on a 2005 study by the Malaria R&D Alliance to establish a …

These documents provide the latest stability data for commonly used vaccines and current research on vaccine formulations and platform technologies. Data are sorted by vaccine in a table format in both documents.

PATH and the US Agency for International Development (USAID) work together to improve global health around the world. This fact sheet highlights the more than 10 PATH projects—including PATH's Malaria Vaccine Initiative—that are …

This article, published in Malaria Journal, analyzed the World Health Organization policy development process to predict its course for a malaria vaccine. Data needs for a malaria vaccine include safety; the demonstration of efficacy in a range of …

This report provides key information on the burden of malaria worldwide, as well as important data on efforts to prevent and control the disease. Also included are detailed profiles of 30 countries with a high burden …

This report summarizes information received from 108 malaria endemic countries and other sources and updates the analysis presented in the 2008 Report. It highlights progress made in meeting the World Health Assembly targets for malaria to be …

This report summarizes information received from 106 malaria-endemic countries and other sources and updates the analyses presented in the 2009 Report. It highlights continued progress made towards meeting the World Health Assembly targets for …